

**Acknowledgement and Consent for Disclosure
of a Waiver under 18 U.S.C. §208(j)(3)**

Bruce G. Pollock, M.D., Ph.D.


Committee: Psychopharmacologic Drugs Advisory Committee

Meeting Date: December 2, 2005

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to new drug application (NDA) 21-514, proposed trade name Methypatch (Methylphenidate Transdermal System, MTS), sponsored by Noven Pharmaceuticals, Inc., and Shire Pharmaceutical Group plc, proposed indication for the treatment of Attention Deficit Hyperactivity Disorder, I am eligible to receive a waiver under 18 U.S.C. 208§ (b)(3).

Type of Interest	Nature	Magnitude
Consulting on an unrelated matter.	Competitor	Less than \$10,001 a year.
Speaker's Bureau on an unrelated matter.	Competitor	Less than \$10,001 a year.

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued. The public disclosure will be accomplished by reading a statement into the record and by FDA making a written copy publicly available at the time of the meeting. I understand that without public disclosure of these interests the waiver is not valid.


Signature of SGE

11/16/05
Date